Greenwich LifeSciences, Inc. (GLSI) intrinsic value & 10-year financials
Greenwich LifeSciences, Inc. (GLSI) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $14.55
- Market cap
- $196.9M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -254.7%
- Free cash flow (FY2025)
- —
GLSI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$19.4M | -$1.43 | — | — | -1340.9% |
| FY2024 | — | -$15.8M | -$1.21 | — | — | -342.0% |
| FY2023 | — | -$8.9M | -$0.69 | — | — | -89.3% |
| FY2022 | — | -$7.8M | -$0.61 | — | — | -39.1% |
| FY2021 | — | -$4.6M | — | — | — | -16.8% |
| FY2020 | — | -$1.9M | — | — | — | -14.2% |
| FY2019 | — | -$3.4M | — | — | — | 59.7% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Greenwich LifeSciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Greenwich LifeSciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -16.6% ROIC.
Greenwich LifeSciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Greenwich LifeSciences, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.